Strength of the evidence: Adjuvant therapy for resected pancreatic cancer

Vincent J. Picozzi; Peter W.T. Pisters; Selwyn M. Vickers; Steven M. Strasberg

doi:10.1007/s11605-007-0446-y

Strength of the evidence: Adjuvant therapy for resected pancreatic cancer

Vincent J. Picozzi, Peter W.T. Pisters, Selwyn M. Vickers, Steven M. Strasberg

Surgical Oncology

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Pancreatic cancer remains one of the greatest challenges within oncology. Among resected patients, 5-year survival is typically only 10-25%. Among eight major randomized trials for resected pancreas cancer, five (GITSG, EORTC, ESPAC-1, RTOG 9704, and CONKO-1), containing a total of over 1,200 patients, have shaped world opinion on this subject. These trials have many significant methodological differences. Major conclusions that can be drawn from these trials in composite are (1) adjuvant chemotherapy is superior to observation following pancreaticoduodenectomy for pancreatic cancer, (2) gemcitabine is superior to 5-FU as adjuvant chemotherapy, and (3) the benefit of adjuvant chemoradiation is uncertain. Additional randomized trials are needed to address significant areas of controversy within available data.

Original language	English (US)
Pages (from-to)	657-661
Number of pages	5
Journal	Journal of Gastrointestinal Surgery
Volume	12
Issue number	4
DOIs	https://doi.org/10.1007/s11605-007-0446-y
State	Published - Apr 2008

Keywords

Adjuvant therapy
Pancreatic cancer
Pancreatic neoplasms
Postgraduate course

ASJC Scopus subject areas

Surgery
Gastroenterology

Access to Document

10.1007/s11605-007-0446-y

Cite this

@article{0aca5201b42f416ab9beb49189ecdf0a,

title = "Strength of the evidence: Adjuvant therapy for resected pancreatic cancer",

abstract = "Pancreatic cancer remains one of the greatest challenges within oncology. Among resected patients, 5-year survival is typically only 10-25%. Among eight major randomized trials for resected pancreas cancer, five (GITSG, EORTC, ESPAC-1, RTOG 9704, and CONKO-1), containing a total of over 1,200 patients, have shaped world opinion on this subject. These trials have many significant methodological differences. Major conclusions that can be drawn from these trials in composite are (1) adjuvant chemotherapy is superior to observation following pancreaticoduodenectomy for pancreatic cancer, (2) gemcitabine is superior to 5-FU as adjuvant chemotherapy, and (3) the benefit of adjuvant chemoradiation is uncertain. Additional randomized trials are needed to address significant areas of controversy within available data.",

keywords = "Adjuvant therapy, Pancreatic cancer, Pancreatic neoplasms, Postgraduate course",

author = "Picozzi, {Vincent J.} and Pisters, {Peter W.T.} and Vickers, {Selwyn M.} and Strasberg, {Steven M.}",

year = "2008",

month = apr,

doi = "10.1007/s11605-007-0446-y",

language = "English (US)",

volume = "12",

pages = "657--661",

journal = "Journal of Gastrointestinal Surgery",

issn = "1091-255X",

publisher = "Springer New York",

number = "4",

}

TY - JOUR

T1 - Strength of the evidence

T2 - Adjuvant therapy for resected pancreatic cancer

AU - Picozzi, Vincent J.

AU - Pisters, Peter W.T.

AU - Vickers, Selwyn M.

AU - Strasberg, Steven M.

PY - 2008/4

Y1 - 2008/4

N2 - Pancreatic cancer remains one of the greatest challenges within oncology. Among resected patients, 5-year survival is typically only 10-25%. Among eight major randomized trials for resected pancreas cancer, five (GITSG, EORTC, ESPAC-1, RTOG 9704, and CONKO-1), containing a total of over 1,200 patients, have shaped world opinion on this subject. These trials have many significant methodological differences. Major conclusions that can be drawn from these trials in composite are (1) adjuvant chemotherapy is superior to observation following pancreaticoduodenectomy for pancreatic cancer, (2) gemcitabine is superior to 5-FU as adjuvant chemotherapy, and (3) the benefit of adjuvant chemoradiation is uncertain. Additional randomized trials are needed to address significant areas of controversy within available data.

AB - Pancreatic cancer remains one of the greatest challenges within oncology. Among resected patients, 5-year survival is typically only 10-25%. Among eight major randomized trials for resected pancreas cancer, five (GITSG, EORTC, ESPAC-1, RTOG 9704, and CONKO-1), containing a total of over 1,200 patients, have shaped world opinion on this subject. These trials have many significant methodological differences. Major conclusions that can be drawn from these trials in composite are (1) adjuvant chemotherapy is superior to observation following pancreaticoduodenectomy for pancreatic cancer, (2) gemcitabine is superior to 5-FU as adjuvant chemotherapy, and (3) the benefit of adjuvant chemoradiation is uncertain. Additional randomized trials are needed to address significant areas of controversy within available data.

KW - Adjuvant therapy

KW - Pancreatic cancer

KW - Pancreatic neoplasms

KW - Postgraduate course

UR - http://www.scopus.com/inward/record.url?scp=40849127035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849127035&partnerID=8YFLogxK

U2 - 10.1007/s11605-007-0446-y

DO - 10.1007/s11605-007-0446-y

M3 - Article

C2 - 18157582

AN - SCOPUS:40849127035

SN - 1091-255X

VL - 12

SP - 657

EP - 661

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

IS - 4

ER -

Strength of the evidence: Adjuvant therapy for resected pancreatic cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this